HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers
HOOKIPA Pharma Inc. (HOOK)
Last hookipa pharma inc. earnings: 3/19 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
New York and VIENNA, Austria, July 11, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA). HB-201 (LCMV) is a TheraT®-based product candidate expressing a non-oncogenic but highly antigenic E6/E7 fusion protein derived from HPV16. In animal models, HB-201 was observed to induce strong immunogenicity, resulting in a robust E6 and E7 antigen specific CD8+ T cell response. HOOKIPA will now start a clinical trial with the goal to provide therapeutic benefit to patients with HPV16+ cancers. Based on the magnitude of response shown in pre-clinical
Show less
Read more
Impact Snapshot
Event Time:
HOOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOOK alerts
High impacting HOOKIPA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
HOOK
News
- Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at HC Wainwright from $6.50 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabGlobeNewswire
- Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers [Yahoo! Finance]Yahoo! Finance
HOOK
Earnings
- 3/22/24 - Miss
HOOK
Sec Filings
- 4/25/24 - Form 8-K
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- HOOK's page on the SEC website